Answers are grounded in this paper and cite their sources.
Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the application of recent data to clinical practice.
No takes yet. Share an insight, caveat, or question.
Rini et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: